16 related articles for article (PubMed ID: 38660670)
1. Clinical biomarkers for thyroid immune-related adverse events in patients with stage III and IV gastrointestinal tumors.
Xing N; Liu J; Hou L; Zhao Y; Ma H; Wang F; Guo Z
Front Immunol; 2024; 15():1381061. PubMed ID: 38774877
[TBL] [Abstract][Full Text] [Related]
2. Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world.
Hao W; Liu W; Chang R; Yang M; Xin K; Liu J; Wang Y; Ren M; Xie J; Yang Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):180. PubMed ID: 38587528
[TBL] [Abstract][Full Text] [Related]
3. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
4. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors.
Bai R; Li L; Chen X; Chen N; Song W; Zhang Y; Lv Z; Han F; Zhao Y; Li W; Cui J
J Oncol; 2021; 2021():9935076. PubMed ID: 34335763
[TBL] [Abstract][Full Text] [Related]
6. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
[TBL] [Abstract][Full Text] [Related]
7. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis of related factors of adverse reactions to immunotherapy in advanced gastric cancer and establishment of a nomogram model.
He XX; Du B; Wu T; Shen H
World J Gastrointest Oncol; 2024 Apr; 16(4):1268-1280. PubMed ID: 38660670
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
